In this portion of the study, patients with cardiovascular disease were not asked whether they were taking triptans, but in a previous report from AMPP, widespread triptan use was seen in migraineurs (Headache 2010;50:256-63).
That study found triptan use in 8.5% of patients with a history of MI, in 7% of those with a history of stroke, in 9% of patients who had undergone heart surgery, in 16% of patients with transient ischemic attacks, and in 18% of patients with a history of claudication.
Merck Sharp & Dohme funded the use of the registry data for this study.* The AMPP study was funded through a research grant to the National Headache Foundation from Ortho-McNeil Neurologics, with additional support provided by Allergan Pharmaceuticals, NuPathe Inc., and Merck Sharp & Dohme. Some of the AMPP investigators, including Dr. Buse, have received research support from Allergan and NuPathe.
* Correction, 11/15/2011: An earlier version of this story incorrectly stated the number and ages of patients who have records in the MORE2 registry, as well as how the use of the registry data was funded.